Harnessing the power of KISIMA® immunisation technology to discover and develop therapeutic vaccines

A novel approach to therapeutic vaccines

AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.

More about AMAL

First-in-class immunisation technology

KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.

More about KISIMA®

Transforming the prospects of cancer patients

We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.

More about portfolio

Latest

News

More news

Events

  • SITC 2023

    November 1-5, 2023 / San Diego / USA

    Matteo Rossi, Head of in vivo Research, presenting

  • mRNA Cancer Vaccines Summit 2023

    October 10-12, 2023 / Boston / USA

    Marie-Laure Santiago-Raber, Senior Director Non-Clinical Development, attending

  • CICON 2023

    September 20-23, 2023 / Milano / Italy

    Elodie Belnoue, Senior Director Translational Research, presenting

More events